Patricia D. Maglalang

Patricia D. Maglalang

Auto-generated profile, based on publicly available information

Patricia D. Maglalang

Eshelman School of Pharmacy, University of North Carolina Chapel Hill North Carolina USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
PMPatricia D. Maglalang
Patricia D. Maglalang
JWJiali Wen
Jiali Wen
CHChristoph P. Hornik
Christoph P. Hornik
DGDaniel Gonzalez
Daniel Gonzalez
Multiple treatment options exist for children with epilepsy, including surgery, dietary therapies, neurostimulation, and antiseizure medications (ASMs). ASMs are the first line of therapy, and more than 30 ASMs have U.S. Food and Drug Administration (FDA) approval for the treatment of various epilepsy and seizure types in children. Given the extensive FDA approval of ASMs in children, it is crucial to consider how the physiological and developmental changes throughout childhood may impact drug disposition. Various sources of pharmacokinetic (PK) variability from different extrinsic and intrinsic factors such as patients' size, age, drug–drug interactions, and drug formulation could result in suboptimal dosing of ASMs. Barriers exist to conducting clinical pharmacological studies in neonates, infants, and children due to ethical and practical reasons, limiting available data to fully characterize these drugs' disposition and better elucidate sources of PK variability. Modeling and simulation offer ways to circumvent traditional and intensive clinical pharmacology methods to address gaps in epilepsy and seizure management in children. This review discusses various physiological and developmental changes that influence the PK and pharmacodynamic (PD) variability of ASMs in children, and several key ASMs will be discussed in detail. We will also review novel trial designs in younger pediatric populations, highlight the role of extrapolation of efficacy in epilepsy, and the use of physiologically based PK modeling as a tool to investigate sources of PK/PD variability in children. Finally, we will conclude with current challenges and future directions for optimizing the efficacy and safety of these drugs across the pediatric age spectrum.

19 September 2024 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
EKEleni Karatza
Eleni Karatza
JSJAYDEEP SINHA
JAYDEEP SINHA
PMPatricia D. Maglalang
Patricia D. Maglalang
AEAndrea Edginton
Andrea Edginton
DGDaniel Gonzalez
Daniel Gonzalez


8 April 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SSSheena Sharma
Sheena Sharma
JGJacqueline Gerhart
Jacqueline Gerhart
IMIris K. Minichmayr
Iris K. Minichmayr
NSNatasha Strydom
Natasha Strydom
PMPatricia D. Maglalang
Patricia D. Maglalang
DLDan Li
Dan Li

29 September 2025 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PMPatricia D. Maglalang
Patricia D. Maglalang
JSJAYDEEP SINHA
JAYDEEP SINHA
VHVictória Etges Helfer
Victória Etges Helfer
AEAndrea Edginton
Andrea Edginton
KZKanecia Zimmerman
Kanecia Zimmerman
DGDaniel Gonzalez
Daniel Gonzalez
Oxcarbazepine (OXC) is a second‐generation antiseizure medication, effective through its active metabolite, 10‐mono‐hydroxy derivative (MHD). OXC is used as adjunctive therapy for focal‐onset and primary generalized tonic–clonic seizures, with recommended dosing based on age and body weight. This study uses physiologically based pharmacokinetic (PBPK) modeling and leverages pharmacokinetic (PK) data acquired from children enrolled in pragmatic trials to understand dosing and subsequent exposure requirements in children with obesity. Drug concentrations of OXC and MHD (n = 148 each) from children with (n = 31) and without (n = 10) obesity, aged 2‐20 years, were collected from two clinical trials (NCT01431326 and NCT02993861) and used for external evaluation of a previously developed PBPK model of OXC using PK‐Sim. We used a previously published virtual population that accounts for the obesity‐related changes in physiology (e.g., liver size and glomerular filtration rate) in children for PK simulations in children with obesity. Model evaluation showed that ≥80% of MHD concentrations contributed by about two thirds of study subjects (26 out of 41) fell within the 90% prediction interval. The PBPK model showed that children with obesity had lower median (interquartile range) simulated weight‐normalized clearance (0.060 L/h/kg [0.048‐0.076 L/h/kg]) than children without obesity (0.067 L/h/kg [0.060‐0.077 L/h/kg]). Simulations revealed that the recommended pediatric dosing regimen produced comparable MHD exposure between children with and without obesity at steady state, supporting its applicability regardless of obesity status. This PBPK‐based dosing aligns with product label recommendations and demonstrates the potential of PBPK modeling for dosing other drugs in children with obesity.

7 January 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
CRChazmyn Riley
Chazmyn Riley
NCNatasha Desiree Casas
Natasha Desiree Casas
PMPatricia D. Maglalang
Patricia D. Maglalang
HSHongyu Su
Hongyu Su
ALAn Le
An Le
MMMaryPeace McRae
MaryPeace McRae
Students and trainees are integral to clinical pharmacology, as they have the potential to shape the field. This perspective highlights how the ASCPT Student and Trainee Community engages members worldwide, providing opportunities and resources to advance scientific and professional development. It also discusses strategies to foster equitable access and how these efforts promote pharmacoequity, including peer mentorship, international engagement, fair access to leadership roles, and diverse representation.